主页 > 医学文档 >
【medical-news】哥伦比亚大学批准了下一代DNA测序
Columbia University licenses next-generation DNA sequencing technology
Columbia University announces today that it recently executed an exclusive license agreement for a next generation DNA sequencing technology to Intelligent Bio-Systems (IBS), Inc. This innovative DNA-sequencing technology was invented by Dr. Jingyue Ju, professor of Chemical Engineering and head of DNA Sequencing and Chemical Biology at the Judith P. Sulzberger, M.D. Columbia Genome Center at Columbia University. The fundamentals of this new technology are being published on-line today by in the Proceedings of the National Academy of Sciences (PNAS). This research paper describes the details of the Sequencing by Synthesis Chemistry and how the approach overcomes accuracy limitations of other next generation DNA sequencing systems.
It was also recently announced that Columbia University in collaboration with the Waltham, Mass. based Intelligent Bio-Systems, is one of only two recipients of the Near-Term Technology Development for Genome Sequencing grants from the National Human Genome Research Institute (NHGRI) of the National Institutes of Health (NIH) (www.genome.gov/19518500). This grant of $425,000 is for the development of a "High-Throughput DNA Sequencing by Synthesis Platform."
"The collaboration between Dr. Ju at Columbia and Intelligent Bio-Systems is an important development to bring this powerful technology to both researchers and clinicians in the near future," said Dr. Steven Gordon, Chief Executive Officer at IBS. "Completing the license was a key step in uniting Dr. Ju's seminal sequencing chemistry and IBS's molecular biology and engineering expertise. We are poised to offer a simple, cost effective platform that will enable many researchers and clinicians to use this next-generation DNA sequencing technology in their own laboratories."
Dr. Ju is a prolific inventor of new technologies for applications in genomics using chemistry and molecular engineering approaches. He is credited with being one of the primary inventors of the fluorescent energy transfer chemistry for 4-color Sanger sequencing being used by virtually all of the current generations of DNA sequencers that were used to complete the Human Genome Project. 本人已认领该文翻译，48小时后若未提交译文，请其他战友自由认领。 Columbia University licenses next-generation DNA sequencing technology
哥伦比亚大学批准了下一代DNA测序工具
Columbia University announces today that it recently executed an exclusive license agreement for a next generation DNA sequencing technology to Intelligent Bio-Systems (IBS), Inc. This innovative DNA-sequencing technology was invented by Dr. Jingyue Ju, professor of Chemical Engineering and head of DNA Sequencing and Chemical Biology at the Judith P. Sulzberger, M.D. Columbia Genome Center at Columbia University. The fundamentals of this new technology are being published on-line today by in the Proceedings of the National Academy of Sciences (PNAS). This research paper describes the details of the Sequencing by Synthesis Chemistry and how the approach overcomes accuracy limitations of other next generation DNA sequencing systems.
今天哥伦比亚大学称最近刚向智能生物系统（IBS）公司授予了一项可作为下一代DNA测序技术的独家许可证。这项革命性的DNA测序技术是由化学工程教授Jingyue Ju博士和哥伦比亚大学哥伦比亚基因组中心DNA测序和生物化学系主任Judith P. Sulzberger博士共同发明的。该项新技术的基本原理今天在网上发表在美国科学院院刊（PNAS）上。这篇研究论文描述了化学合成测序法的详细过程，以及该方法是如何克服其它下一代DNA测序系统的精确度的局限性的。
It was also recently announced that Columbia University in collaboration with the Waltham, Mass. based Intelligent Bio-Systems, is one of only two recipients of the Near-Term Technology Development for Genome Sequencing grants from the National Human Genome Research Institute (NHGRI) of the National Institutes of Health (NIH) (www.genome.gov/19518500). This grant of $425,000 is for the development of a "High-Throughput DNA Sequencing by Synthesis Platform."
据最新消息，哥伦比亚大学正和Waltham, Mass.的智能生物系统公司合作，并成为国立卫生研究所（NIH）国家人类基因组研究院（NHGRI）的近期基因测序技术发展基金项目所资助的仅有的两个项目之一(www.genome.gov/19518500)。该项42500美元的资助基金将用于开发一项“合成平台高流通量DNA测序法”。
"The collaboration between Dr. Ju at Columbia and Intelligent Bio-Systems is an important development to bring this powerful technology to both researchers and clinicians in the near future," said Dr. Steven Gordon, Chief Executive Officer at IBS. "Completing the license was a key step in uniting Dr. Ju's seminal sequencing chemistry and IBS's molecular biology and engineering expertise. We are poised to offer a simple, cost effective platform that will enable many researchers and clinicians to use this next-generation DNA sequencing technology in their own laboratories."
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-05-07 05:14
医学,生命科学网